Search results
Results from the WOW.Com Content Network
Patiromer was generally well tolerated in studies. Side effects that occurred in more than 2% of patients included in clinical trials were mainly gastro-intestinal problems such as constipation, diarrhea, nausea, and flatulence, and also hypomagnesemia (low levels of magnesium in the blood) in 5% of patients, because patiromer binds magnesium in the gut as well.
The mutations in the gene that causes osteoporosis-pseudoglioma either impaire the cells' ability to produce LRP5 protein or they change the single amino acids in the protein. They cannot insert themselves into the outside of the cell, which in turn does not allow them to do their function.
The potassium binder Veltassa is the most selling treatment in the nephrology segment. [ 19 ] CSL Vifor is a member of a number of trade associations that advocate on behalf of the pharmaceutical industry and for the policy positions commonly shared, this includes the European Federation of Pharmaceutical Industries and Associations (EFPIA). [ 20 ]
The North American Association of Central Cancer Registries, Inc. is a professional organization that develops and promotes uniform data standards for cancer registration; provides education and training; certifies population-based registries; aggregates and publishes data from central cancer registries; and promotes the use of cancer surveillance data and systems for cancer control and ...
It was approved for prevention and treatment of osteoporosis and was the first clinically available SERM to prevent both osteoporosis and breast cancer. [7] Ospemifene was approved on February 26, 2013, for the treatment of moderate to severe dyspareunia , which is a symptom, due to menopause , of vulvar and vaginal atrophy .
Strontium ranelate, a strontium(II) salt of ranelic acid, is a medication for osteoporosis marketed as Protelos or Protos by Servier. Studies indicate it can also slow the course of osteoarthritis of the knee. [1] The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by ...
In April 2024, The USPSTF lowered the recommended age to begin breast cancer screening. Citing rising rates of breast cancer diagnosis and substantially higher rates among Black women in the United States, the task force recommends screening mammograms every two years beginning at age 40. This recommendation applies to all cisgender women and ...
Most alternative cancer treatments have not been tested in proper clinical trials. Among studies that have been published, the quality is often poor. A 2006 review of 196 clinical trials that studied unconventional cancer treatments found a lack of early-phase testing, little rationale for dosing regimens, and poor statistical analyses. [11]